What Is Acute Myeloid Leukemia (AML)?
Acute Myeloid Leukemia is a fast-growing cancer of the blood and bone marrow. It develops when immature white blood cells grow out of control and crowd out healthy cells that the body needs to carry oxygen, fight infection, and prevent bleeding.
Because AML progresses quickly, treatment decisions often need to be made soon after diagnosis.
Common Symptoms Patients May Notice
- Ongoing fatigue or weakness
- Frequent infections
- Easy bruising or bleeding
- Shortness of breath
These symptoms happen because leukemia cells replace healthy blood-forming cells.
AML Is Not One Single Disease
Modern medicine has shown that AML is made up of different biological subtypes, often defined by genetic mutations inside leukemia cells. One important mutation involves a gene called IDH1.
Patients whose leukemia carries an IDH1 mutation may benefit from targeted therapy rather than relying only on traditional chemotherapy.
What Is Targeted Therapy?
Unlike chemotherapy, which attacks many fast-growing cells throughout the body, targeted therapies are designed to act on specific molecular changes inside cancer cells.
One such targeted option is:
LUCIVOS (Ivosidenib 250 mg)
LUCIVOS contains Ivosidenib, a medicine that blocks the abnormal IDH1 enzyme. By doing this, it helps leukemia cells mature into more normal blood cells instead of staying stuck in an immature, cancerous state.
When Might LUCIVOS Be Considered?
Doctors may consider LUCIVOS for patients who:
- Have confirmed IDH1-mutated AML
- Are newly diagnosed but not good candidates for intensive chemotherapy
- Have relapsed AML (the disease has returned)
- Have refractory AML (the disease did not respond to prior treatment)
Treatment decisions are always individualized and based on a patient’s overall health, lab results, and treatment history.
Why Genetic Testing Matters
Before starting targeted therapy, doctors perform molecular testing to check for mutations like IDH1. This testing ensures the treatment matches the biology of the leukemia — a key principle of precision medicine.
A More Personalized Path Forward
For patients and families, hearing about genetic mutations can feel overwhelming. But in AML care, this information can open doors to treatments that are:
- More biologically focused
- Often taken orally at home
- Designed to work with the specific disease subtype
Understanding the type of AML you have is an important step toward choosing the most appropriate treatment plan with your healthcare team.
